Comparative treatment persistence of upadacitinib vs. tofacitinib in psoriatic arthritis: a multicenter observational study from the BIRRA cohort - Scorecard - MDSpire

Comparative treatment persistence of upadacitinib vs. tofacitinib in psoriatic arthritis: a multicenter observational study from the BIRRA cohort

  • By

  • Alessandro Conforti

  • Martina Gentile

  • Valerio Cipolloni

  • Linda Lucchetti

  • Marta Priora

  • Andrea Becciolini

  • Eleonora Celletti

  • Miriam Di Penta

  • Alberto Lo Gullo

  • Marino Paroli

  • Elena Bravi

  • Romina Andracco

  • Valeria Nucera

  • Francesca Ometto

  • Federica Lumetti

  • Antonella Farina

  • Matteo Colina

  • Viviana Ravagnani

  • Palma Scolieri

  • Maddalena Larosa

  • Elisa Visalli

  • Olga Addimanda

  • Rosetta Vitetta

  • Alessandro Volpe

  • Alessandra Bezzi

  • Francesco Girelli

  • Aldo Biagio Molica Colella

  • Rosalba Caccavale

  • Eleonora Di Donato

  • Giuditta Adorni

  • Daniele Santilli

  • Gianluca Lucchini

  • Eugenio Arrigoni

  • Emanuela Sabatini

  • Ilaria Platè

  • Natalia Mansueto

  • Aurora Ianniello

  • Enrico Fusaro

  • Maria Chiara Ditto

  • Vincenzo Bruzzese

  • Dario Camellino

  • Gerolamo Bianchi

  • Francesca Serale

  • Rosario Foti

  • Giorgio Amato

  • Francesco De Lucia

  • Ylenia Dal Bosco

  • Roberta Foti

  • Massimo Reta

  • Alessia Fiorenza

  • Guido Rovera

  • Antonio Marchetta

  • Maria Cristina Focherini

  • Fabio Mascella

  • Simone Bernardi

  • Gilda Sandri

  • Dilia Giuggioli

  • Carlo Salvarani

  • Veronica Franchina

  • Francesco Molica Colella

  • Giulio Ferrero

  • Mirco Magnani

  • Marta Maset

  • Camilla Mazzanti

  • Gianluca Santoboni

  • Claudio Angrisani

  • Massimiliano De Simone

  • Bernd Raffeiner

  • Simone Parisi

  • Alarico Ariani

  • July 8, 2026

Share

Clinical Scorecard: Assessment of Treatment Continuation Rates for Upadacitinib and Tofacitinib in Psoriatic Arthritis: Insights from the BIRRA Multicenter Observational Study

At a Glance

CategoryDetail
ConditionPsoriatic Arthritis
Key MechanismsTreatment persistence reflects treatment durability, tolerability, and perceived benefit.
Target PopulationPatients with psoriatic arthritis treated with upadacitinib or tofacitinib.
Care SettingMulticenter observational study across rheumatology centers.

Key Highlights

  • No significant difference in drug persistence between upadacitinib and tofacitinib after adjustment for clinical factors.
  • Concomitant csDMARD therapy and later-line treatment were independent predictors of treatment discontinuation.
  • Retention rates at 6, 12, and 18 months were 86%, 68%, and 54% for upadacitinib and 78%, 60%, and 60% for tofacitinib.

Guideline-Based Recommendations

Diagnosis

  • Confirmed PsA diagnosis based on the CASPAR classification.

Management

  • Initiation of upadacitinib or tofacitinib therapy on or after January 1, 2018.

Monitoring & Follow-up

  • Evaluate treatment persistence and predictors of discontinuation.

Risks

  • Concomitant csDMARDs and later treatment lines significantly reduce persistence.

Patient & Prescribing Data

Adult patients with psoriatic arthritis from 34 rheumatology centers in Italy.

Treatment discontinuation defined as permanent cessation, switching to another biologic or JAK inhibitor, or a treatment gap of more than 60 consecutive days.

Clinical Best Practices

  • Monitor patient demographics and clinical profiles for treatment decisions.
  • Consider the impact of concomitant therapies on treatment persistence.

Related Resources & Content

    Original Source(s)

    Comparative treatment persistence of upadacitinib vs. tofacitinib in psoriatic arthritis: a multicenter observational study from the BIRRA cohort

    • by Alessandro Conforti, Martina Gentile, Valerio Cipolloni, Linda Lucchetti, Marta Priora, Andrea Becciolini, Eleonora Celletti, Miriam Di Penta, Alberto Lo Gullo, Marino Paroli, Elena Bravi, Romina Andracco, Valeria Nucera, Francesca Ometto, Federica Lumetti, Antonella Farina, Matteo Colina, Viviana Ravagnani, Palma Scolieri, Maddalena Larosa, Elisa Visalli, Olga Addimanda, Rosetta Vitetta, Alessandro Volpe, Alessandra Bezzi, Francesco Girelli, Aldo Biagio Molica Colella, Rosalba Caccavale, Eleonora Di Donato, Giuditta Adorni, Daniele Santilli, Gianluca Lucchini, Eugenio Arrigoni, Emanuela Sabatini, Ilaria Platè, Natalia Mansueto, Aurora Ianniello, Enrico Fusaro, Maria Chiara Ditto, Vincenzo Bruzzese, Dario Camellino, Gerolamo Bianchi, Francesca Serale, Rosario Foti, Giorgio Amato, Francesco De Lucia, Ylenia Dal Bosco, Roberta Foti, Massimo Reta, Alessia Fiorenza, Guido Rovera, Antonio Marchetta, Maria Cristina Focherini, Fabio Mascella, Simone Bernardi, Gilda Sandri, Dilia Giuggioli, Carlo Salvarani, Veronica Franchina, Francesco Molica Colella, Giulio Ferrero, Mirco Magnani, Marta Maset, Camilla Mazzanti, Gianluca Santoboni, Claudio Angrisani, Massimiliano De Simone, Bernd Raffeiner, Simone Parisi, Alarico Ariani

    • July 8, 2026

    Related Content

    Efficacy Comparison of Cycling Versus Transitioning to IL-17 Inhibitors Following Initial TNF Inhibitor Failure in Psoriatic Arthritis: A Multicenter Real-World Analysis

    Case report : Early-Onset Juvenile Psoriatic Arthritis Presenting at 15 Months: A Diagnostic Challenge in Infancy

    Psoriasis Biologics Face Off in Drug Survival Study 

    Danish registry data reveal differences in treatment persistence